A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33

Human Genetics

Volumn 127, Issue 1, 2010, Pages 91-99

  Parikh, Hemang ^a   Deng, Zuoming ^a,b   Yeager, Meredith ^a,b   Boland, Joseph ^a,b   Matthews, Casey ^a,b   Jia, Jinping ^a,b   Collins, Irene ^a   White, Ariel ^a   Burdett, Laura ^a   Hutchinson, Amy ^a   Qi, Liqun ^a,b   Bacior, Jennifer A ^a,b   Lonsberry, Victor ^a,b   Rodesch, Matthew J ^c   Jeddeloh, Jeffrey A ^c   Albert, Thomas J ^c   Halvensleben, Heather A ^c   Harkins, Timothy T ^d   Ahn, Jiyoung ^f   Berndt, Sonja I ^a   Chatterjee, Nilanjan ^a   Hoover, Robert ^a   Thomas, Gilles ^a,e   Hunter, David J ^g   Hayes, Richard B ^a,f   Chanock, Stephen J ^a   Amundadottir, Laufey ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Roche NimbleGen Inc   (United States)

^d Roche Applied Science   (United States)

^e INSERM   (France)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 15; KALLIKREIN 2; KALLIKREIN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; KLK15 PROTEIN, HUMAN; TISSUE KALLIKREIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CAUCASIAN; CHROMOSOME 19Q; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CHROMOSOME 19; DNA SEQUENCE; ETHNOLOGY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETICS; HAPLOTYPE; INDEL MUTATION; MUTATION; PROSTATE TUMOR;

CHROMOSOMES, HUMAN, PAIR 19; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; INDEL MUTATION; KALLIKREINS; LINKAGE DISEQUILIBRIUM; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TISSUE KALLIKREINS;

EID: 77449136212     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-009-0751-5     Document Type: Article

References (35)

1. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O, Thomas G, Hunter DJ, Fraumeni JF Jr, Hoover RN, Chanock SJ, Hayes RB (2008) Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 40:1032-1034 (author reply 1035-1036)
2. Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, Richmond TA, Middle CM, Rodesch MJ, Packard CJ, Weinstock GM, Gibbs RA (2007) Direct selection of human genomic loci by microarray hybridization. Nat Methods 4:903-905
3. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319
4. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
5. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388
6. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J (1997) An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11:148-161
7. Couronne O, Poliakov A, Bray N, Ishkhanov T, Ryaboy D, Rubin E, Pachter L, Dubchak I (2003) Strategies and tools for whole-genome alignments. Genome Res 13:73-80
8. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J (2003) Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95:1044-1053
9. Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM (2008) Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev 17:2451-2457
10. Eeles R, Giles G, Neal D, Muir K, Easton DF (2008a) Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer". Nat Genet 40:1035-1036
11. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF (2008b) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316-321
12. Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J, Moss P, Paeper B, Wang K (2000) Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257:119-130
13. Gohagan JK, Prorok PC, Hayes RB, Kramer BS (2000) The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21:251S-272S
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
15. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W (2009) Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5, 895 prostate cancer patients. Prostate 69:1195-1205
16. King DC, Taylor J, Elnitski L, Chiaromonte F, Miller W, Hardison RC (2005) Evaluation of regulatory potential and conservation scores for detecting cis-regulatory modules in aligned mammalian genome sequences. Genome Res 15:1051-1060
17. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC (2007) The diploid genome sequence of an individual human. PLoS Biol 5:e254
18. Lilja H (1985) A kallikrein-like serine protease in prostatic Xuid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903
19. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G (2007) Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25:431-436
20. Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17:873-890
21. Pal P, Xi H, Sun G, Kaushal R, Meeks JJ, Thaxton CS, Guha S, Jin CH, Suarez BK, Catalona WJ, Deka R (2007) Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet 122:251-259
22. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM (2003) Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349:335-342
23. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM (2006) Impact of age, benign prostatic hyperplasia, and cancer on prostate- specific antigen level. Cancer 106:1507-1513
24. Rothberg JM, Leamon JH (2008) The development and impact of 454 sequencing. Nat Biotechnol 26:1117-1124
25. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
27. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR (1996) Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051
28. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O'Hara R, Casalunovo T, Conlin LK, D'Arcy M, Franckelton EC, Geiger EA, Haldeman-Englert C, Imielinski M, Kim CE, Medne L, Annaiah K, BradWeld J, Dabaghyan E, Eckert A, Onyiah CC, Ostapenko S, Otieno FG, Santa E, Shaner JL, Skraban R, Smith RM, Elia J, Goldmuntz E, Spinner NB, Zackai EH, Chiavacci RM, Grundmeier R, Rappaport EF, Grant SF, White PS, Hakonarson H (2009) High-resolution mapping and analysis of copy number variations in the human genome: a data resource for clinical and research applications. Genome Res 19:1682-1690
29. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP (2003) Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 169:361-364
30. Storey JD, Tibshirani R (2003) Statistical signiWcance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445
31. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315
32. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246
33. Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Gronberg H, Isaacs W, Zheng S (2008) Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 14:5819-5824
34. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G (2007) Genome-wide association study of prostate cancer identiWes a second risk locus at 8q24. Nat Genet 39:645-649 (Pubitemid 46676108)
35. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP (2001) Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 276:53-61